Mesoblast (NASDAQ:MESO) Shares Gap Down – Here’s Why

Mesoblast Limited (NASDAQ:MESO)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $11.45, but opened at $10.95. Mesoblast shares last traded at $10.95, with a volume of 49,100 shares.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on MESO shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a report on Thursday, August 29th. StockNews.com lowered Mesoblast from a “hold” rating to a “sell” rating in a research note on Wednesday, September 4th. Maxim Group raised Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research note on Tuesday, September 24th. Finally, Jefferies Financial Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating in a research report on Thursday, August 29th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to MarketBeat, Mesoblast has a consensus rating of “Moderate Buy” and an average price target of $11.50.

Mesoblast Stock Up 0.9 %

The firm has a 50 day moving average price of $9.89 and a two-hundred day moving average price of $7.98. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Perkins Coie Trust Co increased its position in shares of Mesoblast by 15.0% during the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock worth $94,000 after buying an additional 1,500 shares during the period. GAMMA Investing LLC grew its holdings in Mesoblast by 50.1% during the 2nd quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock worth $34,000 after acquiring an additional 1,663 shares during the period. Signaturefd LLC raised its position in shares of Mesoblast by 128.7% in the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after acquiring an additional 3,099 shares in the last quarter. Lazari Capital Management Inc. lifted its stake in shares of Mesoblast by 6.6% in the 2nd quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock valued at $364,000 after purchasing an additional 3,300 shares during the period. Finally, Chapin Davis Inc. boosted its position in shares of Mesoblast by 50.0% during the 2nd quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock valued at $102,000 after purchasing an additional 5,000 shares in the last quarter. Institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.